1 week Ago By Defense World Staff
Prudential Financial Inc. lowered its holdings in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) by 38.
9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 18,200 shares of the company’s stock after selling 11,600 shares during the quarter. Prudential Financial Inc.
’s holdings in Ikena Oncology were worth $30,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also bought and sold shares of IKNA. BML Capital Management LLC lifted its stake in Ikena Oncology by 395.
8% in the fourth quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after acquiring an additional 2,862,578 shares during the period. Peapod Lane Capital LLC purchased a new stake in shares of Ikena Oncology in the 4th quarter worth about $833,000.
FMR LLC boosted its stake in shares of Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after purchasing an additional 18,607 shares in the last quarter.
Finally, Geode Capital Management LLC increased its position in shares of Ikena Oncology by 5.6% during the third quarter. Geode Capital Management LLC now owns 271,026 shares of the company’s stock valued at $469,000 after buying an additional 14,319 shares during the period.
Hedge funds and other institutional investors own 75.00% of the company’s stock. Ikena Oncology Trading Up 3.
8 %Shares of IKNA stock opened at $1.10 on Friday. The company’s fifty day moving average price is $1.
33 and its 200-day moving average price is $1.54. The stock has a market cap of $53.
08 million, a PE ratio of -0.89 and a beta of 0.48.
Ikena Oncology, Inc. has a 12 month low of $0.97 and a 12 month high of $1.
94. Ikena Oncology (NASDAQ:IKNA – Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.
18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05.
On average, sell-side analysts forecast that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.
Analyst Ratings ChangesSeparately, Wedbush reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a research report on Monday, December 23rd.Check Out Our Latest Report on Ikena OncologyIkena Oncology Profile (Free Report)Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.
Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.Read MoreFive stocks we like better than Ikena OncologyInsider Buying Explained: What Investors Need to KnowJPMorgan is a Buy, if You Can Handle The Volatility Why is the Ex-Dividend Date Significant to Investors?United States Steel’s Crash: An Unmissable Buying Opportunity3 Warren Buffett Stocks to Buy NowRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
